Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 5 30 versus TRI SPRINTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 5 30 versus TRI SPRINTEC.
JUNEL 1.5/30 vs TRI-SPRINTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
None Documented
None Documented
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days.
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive